The transfusion independence that patients could achieve with Geron Corporation’s proposed anemia treatment imetelstat won over the US Food and Drug Administration’s Oncologic Drugs Advisory Committee despite several product safety concerns.
Geron has offered imetelstat, proposed trade name Rytelo, for transfusion-dependent anemia in adults with low- to immediate-1 risk myelodysplastic syndromes (MDS) who failed to respond, or have lost